Ming-Chih Hou
Ming-Chih Hou is an expert in Gastroenterology at Taipei Veterans General Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Ming-Chih Hou in the top 1% of experts worldwide for Liver Neoplasms and Carcinoma, and in the top 1% of experts in Taiwan for Varicose Veins. Ming-Chih Hou has authored 492 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 2 of them ongoing. SLR score: 1,658 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Hepatology - Oncology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 492
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Integrated microbiome and metabolomic profiling reveals alterations across the adenoma-colorectal cancer sequence. PMID 42929529 — genes, genes, rrna, bile, amino acids, fatty acids, volatile, neoplasms, biomarkers, metabolomics, adenoma, colorectal neoplasms, carbohydrates, gastrointestinal microbiome, microbiota, fatty acids | Microbiol Spectr | 2026 | 0 |
| Nonselective beta-blockers and hepatic encephalopathy in liver cirrhosis:A meta-analysis of randomized controlled trials. PMID 42870342 — bias, liver, brain diseases, therapeutics, hepatic encephalopathy | J Chin Med Assoc | 2026 | 0 |
| CATS-BIT-ME Score: A Machine Learning and Conventional Risk Model for Prognosis in Hepatocellular Carcinoma. PMID 42725053 — carcinoma, hepatocellular, biomarkers, machine learning, learning, prognosis | Gastro Hep Adv | 2026 | 0 |
| An in-hospital referral program for hepatitis c virus elimination in patients with type 2 diabetes mellitus. PMID 42478039 — diabetes mellitus, hepatitis c, kidney, viremia, viruses, therapeutics, hepatitis, diabetes mellitus, type 2 | J Chin Med Assoc | 2026 | 0 |
| Interactive Roles of Metabolic Dysfunction-Associated Steatotic Liver Disease and Nutritional Status in the Prognosis of Patients With Hepatocellular Carcinoma After Surgical Resection. PMID 42400215 — liver diseases, carcinoma, hepatocellular, liver, protective factors, nutritional status, prognosis, hepatitis | Kaohsiung J Med Sci | 2026 | 0 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non responders NCT06594783 — carvedilol, hypertension, safety, hemorrhage, fibrosis, signs and symptoms, esophageal and gastric varices, hypertension, portal, ligation, primary prevention, varicose veins, non-responder | Phase 4 | Recruiting | 2025 |
| Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC NCT06594744 — carvedilol, hypertension, carcinoma, hepatocellular, safety, hemorrhage, blood, absenteeism, bradycardia, heart rate, heart, blood pressure, signs and symptoms, esophageal and gastric varices, hypertension, portal, ligation, hypotension, outpatients, varicose veins, carcinoma | Phase 4 | Recruiting | 2024 |
LeadR Networks
Main global connection map